Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease

被引：23
|
作者：
Mian, S
Baron, H
机构：
[1] Pediat Gastroenterol & Nutr Assoc, Las Vegas, NV 89109 USA
[2] Univ Nevada, Sch Med, Dept Pediat, Reno, NV 89557 USA
来源：
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 2005年 / 41卷 / 03期
关键词：
D O I：
10.1097/01.mpg.0000169275.86308.b0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：357 / 359
页数：3
相关论文
共 50 条
  • [21] EVALUATION OF ADALIMUMAB EFFECTIVENESS IN ANTI-TUMOR NECROSIS FACTOR-NAIVE PEDIATRIC PATIENTS WITH CROHN'S DISEASE IN CLINICAL PRACTICE
    Steiner, Steven J.
    King, Eileen
    Park, K. T.
    Pashankar, Dinesh
    Shashidhar, Harohalli
    Sudel, Boris
    Eichner, Samantha
    Chen, Shiran
    Pratt, Jesse
    Colletti, Richard B.
    GASTROENTEROLOGY, 2017, 152 (05) : S954 - S955
  • [22] Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody
    Wollina, U
    Konrad, H
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2002, 16 (02) : 127 - 129
  • [23] Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naive pediatric patients with Crohn's disease in clinical practice
    Steiner, S.
    King, E.
    Park, K.
    Pashankar, D.
    Shashidhar, H.
    Sudel, B.
    Eichner, S.
    Chen, S.
    Pratt, J.
    Colletti, R.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S15 - S16
  • [24] Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
    Min Seob Kwak
    Hun Hee Lee
    Jae Myung Cha
    Hyun Phil Shin
    Jung Won Jeon
    Jin Young Yoon
    Scientific Reports, 10
  • [25] Novel candidate drugs in anti-tumor necrosis factor refractory Crohn's diseases: in silico study for drug repositioning
    Kwak, Min Seob
    Lee, Hun Hee
    Cha, Jae Myung
    Shin, Hyun Phil
    Jeon, Jung Won
    Yoon, Jin Young
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease
    Sack, MN
    PHARMACOLOGY & THERAPEUTICS, 2002, 94 (1-2) : 123 - 135
  • [27] Case Report: Post-Liver Transplant Crohn's Disease Refractory to Anti-tumor Necrosis Factor Agents
    Yilmaz, Yusufcan
    Keskin, Onur
    Toruner, Murat
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1561 - S1561
  • [28] Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn's disease
    Thomas, CW
    Weinshenker, BG
    Sandborn, WJ
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (01) : 28 - 31
  • [29] Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab
    Korzenik, JR
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) : 285 - +
  • [30] Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies
    Di Sabatino, Antonio
    Pender, Sylvia L. F.
    Jackson, Claire L.
    Prothero, Joanna D.
    Gordon, John N.
    Picariello, Lucia
    Rovedatti, Laura
    Docena, Guillermo
    Monteleone, Giovanni
    Rampton, David S.
    Tonelli, Francesco
    Corazza, Gino R.
    Macdonald, Thomas T.
    GASTROENTEROLOGY, 2007, 133 (01) : 137 - 149
12345